$AGEN Cashflow Statement | Understand Stock

$AGEN

$6.16 -$0.17 (2.69%) Close

$AGEN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Share-based compensation
Non-cash royalty revenue
Non-cash interest expense
Loss (gain) on sale or disposal of assets, net
Gain from deconsolidation of MiNK Therapeutics, Inc.
Loss on impairment of assets
Gain on partial forgiveness of liability
Gain on forgiveness of liability
Loss on modification of debt
Gain on extinguishment of debt
Gain on lease terminations
Unrealized loss on long-term investments
Fair value adjustments
Other, net

Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses
Accounts payable
Deferred revenue
Accrued liabilities and other current liabilities
Other operating assets and liabilities
Net cash used in operating activities
Cash flows from investing activities:
Proceeds from sale of property, plant and equipment
Purchases of property, plant and equipment
Purchases of available-for-sale securities
Proceeds from sale of available-for-sale securities
Purchase of long-term investment
Proceeds from sale of long-term investment
Cash paid for business acquisition, net
Net cash provided by investing activities

Cash flows from financing activities:
Net proceeds from sale of equity
Net proceeds from sale of subsidiary shares in private placement
Proceeds from employee stock purchases and option exercises
Purchase of treasury shares to satisfy tax withholdings
Purchase of subsidiary shares
Proceeds from Ligand Purchase Agreement, net of expenses
Proceeds from the issuance of long-term debt, net
Impact to cash resulting from deconsolidation certain subsidiaries
Payment of long-term debt
Payment of finance lease obligations
Net proceeds from sale of subsidiary shares in an initial public offering
Payment of contingent purchase price consideration
Repayments of debt
Net cash provided by financing activities

Effect of exchange rate changes on cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental cash flow information:
Cash paid for interest
Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities
Conversion of series C-1 convertible preferred stock to common stock, $0.01 par value
Issuance of stock options for payment of certain employee bonuses
Issuance of common stock
Employee Bonus
Payment for Services
Milestone Achievement
Long-Term Debt

Issuance of subsidiary stock options for payment of certain employee bonuses
Issuance of subsidiary shares for employee bonus
Insurance financing agreements
Lease right-of-use assets obtained in exchange for new operating lease liabilities
Lease right-of-use assets obtained in exchange for new finance lease liabilities

Comments